Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance

被引:16
作者
Roh, Yun-Gil [1 ]
Mun, Jeong-Yeon [1 ]
Kim, Seon-Kyu [2 ,3 ]
Park, Won Young [4 ]
Jeong, Mi-So [1 ]
Kim, Tae Nam [5 ]
Kim, Won-Tae [1 ]
Choi, Yung Hyun [6 ]
Chu, In-Sun [3 ,7 ]
Leem, Sun-Hee [1 ]
机构
[1] Dong A Univ, Dept Biol Sci, Busan 49315, South Korea
[2] Korea Res Inst Biosci & Biotechnol KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea
[3] Korea Univ Sci & Technol, KRIBB Sch Biosci, Dept Bioinformat, Daejeon 34113, South Korea
[4] Pusan Natl Univ Hosp, Med Res Inst, Dept Pathol, Busan 49241, South Korea
[5] Pusan Natl Univ Hosp, Med Res Inst, Dept Urol, Busan 49241, South Korea
[6] Dong Eui Univ, Coll Korean Med, Dept Biochem, Busan 47227, South Korea
[7] Korea Res Inst Biosci & Biotechnol KRIBB, Genome Editing Res Ctr, Daejeon 34141, South Korea
基金
新加坡国家研究基金会;
关键词
bladder cancer; FOXM1; FANCD2; Fanconi anemia pathway; DNA repair; cancer recurrence; TRANSCRIPTION FACTOR FOXM1; FORKHEAD BOX M1; DNA-DAMAGE; MASTER REGULATOR; EXPRESSION; PROGRESSION; APOPTOSIS; CELLS; EPIDEMIOLOGY; GUIDELINES;
D O I
10.3390/cancers12061417
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although the 5-year survival rate of patients diagnosed with nonmuscle invasive bladder cancer (NMIBC) has reached 85%, more than 50% of patients suffer from frequent recurrences. To identify molecular targets associated with recurrence of NMIBC, we analyzed gene expression data and found that FOXM1 and FANCD2 were involved in recurrence. Therefore, we investigated how these genes were involved in the mechanism of recurrence and confirmed their usefulness as biomarkers. Investigation have shown that FOXM1 directly regulated the transcription of FANCD2, which is the key gene of the Fanconi anemia (FA) pathway. Depletion of FOXM1 resulted in DNA repair defects in the FA pathway and in decreased resistance to chemotherapy. Thus, the FANCD2-associated FA pathway activated by FOXM1 is an important mechanism involved in chemotherapy-related recurrence. In conclusion, FOXM1 and FANCD2 can be used as prognostic factors that are associated with high risk of recurrence and with anticancer drug resistance properties in NMIBC patients.
引用
收藏
页码:1 / 20
页数:19
相关论文
共 50 条
  • [31] FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy
    Lin, Jian-zhong
    Wang, Wei-wan
    Hu, Ting-ting
    Zhu, Gang-yi
    Li, Li-nan
    Zhang, Cheng-yang
    Xu, Zheng
    Yu, Hong-bo
    Wu, Hong-fei
    Zhu, Jia-geng
    [J]. CANCER LETTERS, 2020, 469 : 481 - 489
  • [32] GTSE1 promotes prostate cancer cell proliferation via the SP1/FOXM1 signaling pathway
    Lai, Wenjie
    Zhu, Weian
    Li, Xiaojuan
    Han, Yuefu
    Wang, Yu
    Leng, Qu
    Li, Mingzhao
    Wen, Xingqiao
    [J]. LABORATORY INVESTIGATION, 2021, 101 (05) : 554 - 563
  • [33] Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer
    Huang, Shujun
    Hu, Pingzhao
    Lakowski, Ted M.
    [J]. PHARMACOGENOMICS JOURNAL, 2023, 23 (04) : 61 - 72
  • [34] Knockdown of FOXM1 suppresses cell growth and metastasis in human laryngeal cancer via the AKT signaling pathway
    Yan, J.
    Hou, J.
    Yan, Y.
    Ren, X-Y
    Luo, H-N
    Wang, Z-G
    Zheng, G-X
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (12) : 6786 - 6793
  • [35] FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer
    Guan, Shaoxing
    Chen, Xi
    Chen, Youhao
    Xie, Wen
    Liang, Heng
    Zhu, Xia
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhao, Hongyun
    Zhuang, Wei
    Liu, Shu
    Huang, Min
    Wang, Xueding
    Zhang, Li
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3770 - 3784
  • [36] HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells
    Yang, Dong
    Ma, Yan
    Zhao, Pengcheng
    Ma, Jing
    He, Chaohong
    [J]. EXPERIMENTAL CELL RESEARCH, 2021, 408 (02)
  • [37] Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a
    Jiang, Ling
    Cao, Xiao-Cheng
    Cao, Jian-Guo
    Liu, Fei
    Quan, Mei-Fang
    Sheng, Xi-Feng
    Ren, Kai-Qun
    [J]. ONCOLOGY LETTERS, 2013, 5 (05) : 1605 - 1610
  • [38] Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance
    Khongkow, P.
    Gomes, A. R.
    Gong, C.
    Man, E. P. S.
    Tsang, J. W-H
    Zhao, F.
    Monteiro, L. J.
    Coombes, R. C.
    Medema, R. H.
    Khoo, U. S.
    Lam, E. W-F
    [J]. ONCOGENE, 2016, 35 (08) : 990 - 1002
  • [39] FOXM1, a super enhancer-associated gene, is related to poorer prognosis and gemcitabine resistance in pancreatic cancer
    Jiang, Jian
    Shen, Tianci
    Chen, Dan
    Dai, Zihao
    Wang, Xuelong
    Meng, Qiang
    Yang, Zhuo
    Zhang, Di
    Guo, Xiaoyi
    Xu, Jianqiang
    Gu, Jiangning
    Wang, Changmiao
    [J]. CELL BIOCHEMISTRY AND BIOPHYSICS, 2025, : 2441 - 2452
  • [40] Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells
    Ahmed, Maqbool
    Hussain, Azhar R.
    Siraj, Abdul K.
    Uddin, Shahab
    Al-Sanea, Nasser
    Al-Dayel, Fouad
    Al-Assiri, Mohammed
    Beg, Shaham
    Al-Kuraya, Khawla S.
    [J]. MOLECULAR CANCER, 2015, 14